What is retatrutide?
Retatrutide (internal code LY3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly, engineered to activate three metabolic receptors simultaneously: GLP-1, GIP, and glucagon (GCGR). That triple affinity is what sets it apart from every other incretin on the market — semaglutide (GLP-1 only), tirzepatide (GLP-1 + GIP) — and is the reason the 2023 Phase 2 results made the cover of the New England Journal of Medicine.
In research-use-only (RUO) settings, retatrutide is studied for body weight regulation, hepatic steatosis reversal, metabolic syndrome, and glycemic control. Storage is stable lyophilized at 2–8°C; once reconstituted with bacteriostatic water, solution stability reaches 28 days at 2–8°C. Lab Peptides France ships every batch with a certified COA (HPLC ≥98% purity) — no gray-market powder, no vague labels.
Triple agonist mechanism: GLP-1 / GIP / GCGR
GLP-1
Slows gastric emptying, enhances glucose-dependent insulin secretion, suppresses appetite via hypothalamic POMC/AgRP neurons.
GIP
Amplifies insulin response in fed state, modulates adipose tissue metabolism, reduces inflammation markers in obesity models.
Glucagon (GCGR)
Increases resting energy expenditure (REE), promotes hepatic fat oxidation, accelerates reversal of liver steatosis.
The glucagon component is the real lever: it lifts basal metabolism while GLP-1/GIP cut intake — a caloric deficit from both sides. No other research peptide on the 2025 market plays all three channels at once.
Clinical studies 2023-2024
Jastreboff et al. — NEJM 2023
Phase 2 · n=338Double-blind placebo-controlled trial across 48 weeks of dose-escalation (up to 12mg weekly). Primary endpoint: body weight reduction.
- -24.2% body weight @ 12mg / 48 weeks
- -17.5% body weight @ 8mg / 48 weeks
- 100% of subjects lost ≥5% weight
Sanyal et al. — The Lancet 2024
Phase 2 · NAFLD · n=98Targeted non-alcoholic fatty liver disease (NAFLD/MASH) with 48-week retatrutide dosing. MRI-measured hepatic fat fraction as primary endpoint.
- -81.4% hepatic fat fraction @ 8mg
- 85% of subjects reached ≥30% fat reduction
TRIUMPH Phase 3 ongoing — Eli Lilly's pivotal program (TRIUMPH-1, 2, 3, 4, 5) will read out through 2026-2027, covering obesity, type 2 diabetes, NAFLD/MASH, and cardiovascular outcomes. Retatrutide is positioned as the successor to tirzepatide.
Choose your retatrutide dose
Six formats cover every research protocol — from pilot exploration (5mg) to extended multi-week studies (40mg). Each vial is HPLC ≥98%, COA-certified, and shipped discreetly from France.
Retatrutide 5mg
PilotShort format to initiate an escalation protocol (1-2 weeks). Ideal first cycle.
View productRetatrutide 10mg
Best-sellerFlagship format — Sanyal 2024 dose (−81.4% hepatic fat). Covers 5-8 weeks.
View productRetatrutide 20mg
Volume format for long cycles (8-12 weeks) or multi-subject protocols.
View productRetatrutide 30mg
Lab-scale format for high cumulative-dose research protocols.
View productRetatrutide 40mg
MaxMaximum format — extended protocols 12+ weeks, best €/mg ratio on the market.
View productWhy Lab Peptides France
HPLC ≥98% purity, every batch
Third-party HPLC-MS certification. COA downloadable on every product page, batch number traceable.
Stocked in France
Cold-chain packaging, discrete neutral boxes, stocked in France (no customs). Dispatches leave Tuesday and Friday, then 2 to 3 business days with Colissimo. Tracking included.
French-speaking support
Team based in Europe, replies under 4h on weekdays. Technical questions, reconstitution guidance, order tracking.
5% automatic cashback
Every paid order credits 5% of its subtotal to your loyalty balance, convertible into a promo code from 5 €. Card, Apple Pay and Google Pay accepted.
Ready to order?
Most popular format in 2025 research: retatrutide 10mg (flagship). One vial covers a typical 5-8 week escalation protocol.
Order Retatrutide 10mgFrequently asked questions
Is retatrutide legal in France?
Yes, as a research compound (RUO) intended exclusively for laboratory use. It is not approved as a medicine, so sale and possession for research are legal; any human, veterinary, or therapeutic use is prohibited.
How does it differ from semaglutide and tirzepatide?
Semaglutide activates one receptor (GLP-1), tirzepatide activates two (GLP-1 + GIP), retatrutide activates three (GLP-1 + GIP + glucagon). This triple action explains body-weight results ~40% higher than tirzepatide in comparable Phase 2 trials.
How to reconstitute retatrutide?
Use sterile bacteriostatic water, typical ratio 2ml per 10mg (final concentration 5mg/ml). Inject water against the vial wall, do not shake, let it sit 2 minutes. Stable 28 days at 2–8°C after reconstitution. Full guide on our /en/reconstitution-guide page.
Which dose for a first cycle?
For a short pilot protocol, start with the 5mg. For a standard research cycle (5-8 weeks), the 10mg is the most common choice in 2025. 15mg+ formats are reserved for long or multi-subject protocols.
Do you ship to France? How fast?
Yes. Dispatches leave Tuesday and Friday, then allow 2 to 3 business days with Colissimo. Stocked in France, no customs. Discrete packaging, cold chain preserved, tracking included. Permanent stock on all 6 doses.
Which payment methods do you accept?
Card (Visa, Mastercard, CB), Apple Pay and Google Pay. Every paid order credits 5% of its subtotal to your loyalty balance, convertible into a promo code from 5 €.
Will I receive a Certificate of Analysis (COA)?
Every batch ships with a third-party COA (HPLC-MS, ≥98% purity), downloadable directly from the product page before purchase. Batch number is traceable.
Where does retatrutide stand in Phase 3?
Eli Lilly is running the pivotal TRIUMPH program (1 to 5) covering obesity, type 2 diabetes, NAFLD/MASH and cardiovascular. Readouts expected 2026-2027. Market approval anticipated after TRIUMPH-1 (obesity).